After graduating from Temple University in 2023, the South Philadelphia local was finding her footing in post-grad life while ...
Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...
The phase 3 KEYNOTE‑B96 trial showed that Keytruda plus paclitaxel, with or without Avastin, improved overall survival in patients with platinum‑resistant ovarian cancer. From your perspective, what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results